DexCom (DXCM) has drawn fresh attention after multiple analysts shifted to “Outperform.” This coincides with robust Q1 2026 revenue of US$1.19b and the launch of Dexcom Flex for adults with Type 2 diabetes.

At a share price of US$72.10, DexCom has seen strong short term momentum, with a 7 day share price return of 10.77% and 30 day share price return of 17.10%. This is despite the 1 year total shareholder return being down 14.68% and the 3 year total shareholder return being down 37.33%, suggesting that recent enthusiasm around Q1 results, analyst upgrades and the Dexcom Flex launch contrasts with a weaker longer term record.

If DexCom’s recent move has you looking across healthcare technology, this is a good moment to broaden your watchlist with our screener of 34 healthcare AI stocks

Recent upgrades, a fresh US$1,000m buyback plan and the Dexcom Flex launch have all swung sentiment back in DexCom’s favor. The key question is whether the stock is still trading at a discount or if markets are already pricing in future growth.

Most Popular Narrative: 13.7% Undervalued

DexCom’s most followed narrative pegs fair value at about $83.54, compared with the last close at $72.10, which sets up a clear valuation gap for investors to weigh.

The recent expansion of insurance reimbursement for type 2 non-insulin diabetes patients, now covering nearly 6 million lives across the three largest U.S. PBMs, opens a large, previously untapped segment of DexCom's addressable market, driving new patient growth and supporting robust multi-year revenue expansion. Growing global recognition of CGM efficacy, with recent clinical trial evidence and expanded coverage in international markets (e.g., France, Japan, and Ontario, Canada), positions DexCom to penetrate underpenetrated regions and diversify revenue streams, creating sustainable top-line growth.

Want to see what is behind that growth story and valuation gap? The narrative leans heavily on multi year revenue expansion, rising margins, and a richer earnings multiple.

At the core of this narrative is a discounted cash flow style view that relies on future cash generation, using a 7.67% discount rate to translate those expectations back to today. Analysts feeding into this view are building in ongoing double digit revenue growth, margin improvement from current levels, and a future P/E that sits above the broader US Medical Equipment group, which helps explain why the fair value estimate sits comfortably above the current share price.

Result: Fair Value of $83.54 (UNDERVALUED)

However, investors also need to weigh potential pressure from CMS competitive bidding on CGM pricing, as well as the risk that rival sensors could chip away at DexCom’s core market.

Next Steps

Curious whether this upbeat narrative really holds up for your own portfolio? Take a closer look at the data, pressure test the assumptions, and see what stands out in our breakdown of 3 key rewards

Looking for more investment ideas?

If DexCom has sharpened your focus, do not stop here. Broaden your opportunity set now so you are not relying on a single stock story.

• Spot potential bargains early by scanning our list of screener containing 21 high quality undiscovered gems before wider attention arrives.
• Strengthen your portfolio core by focusing on companies in the solid balance sheet and fundamentals stocks screener (46 results) that may better handle financial stress.
• Target stability with income by reviewing the 10 dividend fortresses that combine yield with resilience.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.